Skip to main content
S&P 5007,591.70-0.58%DOW52,064.10-0.60%NASDAQ26,081.72-0.65%BTC$76,799.00-1.71%ETH$2,453.65-0.48%GOLD$4,367.20-0.91%OIL$103.26+0.76%
Smart Investors Daily
DY

NASDAQ · DYN

Dyne Therapeutics, Inc.

Healthcare · Biotechnology

$18.42

Down-$0.77 (-4.01%)

Updated Sep 11, 2026, 4:06 AM

SID Score

4.8/10

Composite research score

Smart Money

58/100

Neutral

Market cap
2.77B
P/E ratio
-5.35
Dividend yield
0.00%
52-week range
$14.96 – $27.31
Volume
4.71M
Avg. volume
2.94M

Price performance

DYN price history

1M range · 20 trading sessions · Daily adjusted prices

DYN closed at $18.42 after 20 trading sessions, down 29.04% for the selected period.

Last close
$18.42
Period change
-29.04%
Period low
$18.42
Period high
$26.78
Daily close
View OHLC price history
DYN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 10, 2026$19.025$19.025$17.93$18.424.71M
Sep 9, 2026$19.38$20.16$18.97$19.195.14M
Sep 8, 2026$17.08$20.91$17.002$20.3117.17M
Sep 4, 2026$24.59$24.70$24.14$24.281.59M
Sep 3, 2026$25.26$25.39$24.60$24.951.45M
Sep 2, 2026$25.55$26.18$24.92$25.142.18M
Sep 1, 2026$24.99$25.40$24.72$25.101.63M
Aug 31, 2026$24.92$25.65$24.58$25.432.77M
Aug 28, 2026$25.82$25.98$24.83$25.071.19M
Aug 27, 2026$26.29$26.49$25.975$26.091.02M
Aug 26, 2026$26.32$26.474$25.78$26.361.53M
Aug 25, 2026$26.28$26.69$25.965$26.341.46M
Aug 24, 2026$26.13$26.135$25.14$25.991.37M
Aug 21, 2026$26.215$26.87$26.02$26.101.18M
Aug 20, 2026$26.33$26.43$25.675$25.981.48M
Aug 19, 2026$26.50$26.94$25.98$26.781.95M
Aug 18, 2026$25.875$26.31$25.46$26.001.9M
Aug 17, 2026$25.8978$26.43$25.30$26.151.32M
Aug 14, 2026$25.73$25.93$25.30$25.701.68M
Aug 13, 2026$26.00$26.48$25.875$25.961.9M

Latest DYN news

The latest Smart Investors Daily articles mentioning DYN.

Stock researchCompany · Overview

DYN research

Overview

Company profile and research snapshot.

Company profile

Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$38.11
Implied upside
—
Analysts
—
DYN recent ratings
DateFirmRatingTarget
Sep 9, 2026BairdOutperform—
Sep 9, 2026RBC CapitalOutperform—
Jul 31, 2026Morgan StanleyOverweight—
Jul 30, 2026RBC CapitalOutperform—
Jul 23, 2026Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting

- Data support the ongoing development of four investigational therapies for DMD amenable to skipping of exons 53, 45, 44 or 55, all of which are advancing into IND-enabling studies - - All development candidates leverage the same FORCE™ platform as zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), which is under FDA review for exon 51 DMD - WALTHAM, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering funct

Yahoo · Sep 2, 2026

Dyne Therapeutics to Participate in Upcoming Investor Conferences

WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, fireside chat on Friday, September 11, 2026 at 10:20 a.m. ET in New York, NYMorgan Stanley 24th Annual Global Healthcare Con

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By